Attach to Form 990 or Form 990-EZ.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i)Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Total | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any unusual grants.) .... | 156,880,684 | 146,497,371 | 146,698,221 | 244,026,040 | 112,703,072 | 806,805,388 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 156,880,684 | 146,497,371 | 146,698,221 | 244,026,040 | 112,703,072 | 806,805,388 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 95,508,970 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 711,296,418 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 156,880,684 | 146,497,371 | 146,698,221 | 244,026,040 | 112,703,072 | 806,805,388 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 4,402,201 | 4,000,400 | 4,044,153 | 6,992,391 | 5,532,193 | 24,971,338 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | |||||
| 11 | Total support. Add lines 7 through 10. | 832,329,843 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2015 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2015 |
(iii) Distributable Amount for 2015 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2015 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2015 (reasonable cause required--see instructions) |
||||
| 3 Excess distributions carryover, if any, to 2015: | ||||
| a | ||||
| b | ||||
| c | ||||
| d From 2013....... | ||||
| e From 2014....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2015 distributable amount | ||||
|
i
Carryover from 2010 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2015 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2015 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2015, if any. Subtract lines 3g and 4a from line 2 (if amount greater than zero, see instructions) |
||||
|
6
Remaining underdistributions for 2015. Subtract lines 3h and 4b from line 1 (if amount greater than zero, see instructions) |
||||
|
7 Excess distributions carryover to 2016. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a | ||||
| b | ||||
| c Excess from 2013....... | ||||
| d From 2014....... | ||||
| e From 2015....... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| FORM 990, PART I, LINE 1 & PART III, LINE 1 | ORGANIZATIONS MISSION SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. |
| FORM 990, PART III, LINE 4 | PROGRAM SERVICE ACCOMPLISHMENTS SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (SBP) IS AN INDEPENDENT NONPROFIT MEDICAL RESEARCH ORGANIZATION THAT CONDUCTS WORLD-CLASS, COLLABORATIVE, BIOLOGICAL RESEARCH AND TRANSLATES ITS DISCOVERIES FOR THE BENEFIT OF PATIENTS. SBP FOCUSES ITS RESEARCH ON CANCER, IMMUNITY, NEURODEGENERATION, METABOLIC DISORDERS AND RARE CHILDRENS DISEASES. CANCER RESEARCH UNCOVERS DEFENDER AGAINST CANCER-PROMOTING LIVER DAMAGE. LIVER CANCER IS ONE OF THE FEW CANCER TYPES FOR WHICH MORTALITY RATES ARE ACTUALLY INCREASING IN THE U.S. MOST CASES ARISE FOLLOWING LIVER DAMAGE BY VIRUSES, ALCOHOL OR FAT ACCUMULATION DUE TO OBESITY. THIS DAMAGE LEADS TO INFLAMMATORY SIGNALS THAT HELP FUEL TUMORS. JORGE MOSCAT, PH.D., AND MARIA DIAZ-MECO, PH.D., PUBLISHED RESEARCH IN 'CANCER CELL' SHOWING HOW A PROTEIN CALLED P62, WHEN LOCATED IN THE TISSUE SURROUNDING A TUMOR, CAN ACTUALLY DAMPEN THE PRODUCTION OF TUMOR-STIMULATING INFLAMMATORY SIGNALS. THE FINDINGS SUGGEST THAT DRUGS AIMED AT INCREASING THE LEVELS OF P62 IN LIVER TISSUE SURROUNDING TUMORS MAY BLOCK LIVER CANCER PROGRESSION. TUMOR SURVIVAL STRATEGY POINTS TO NEW DRUG TARGET. TUMORS HAVE THE UNIQUE ABILITY TO SURVIVE EVEN WHEN SUPPLIES OF OXYGEN ARE LOW - A CONDITION CALLED HYPOXIA - BY PRODUCING A PROTEIN CALLED HYPOXIA INDUCIBLE FACTOR-1 (HIF-1). THOUGH BLOCKING HIF-1 WOULD KILL HYPOXIC TUMORS, FINDING DRUGS THAT ACHIEVE THIS HAS SO FAR PROVEN DIFFICULT. GARTH POWIS, PH.D., PUBLISHED A STUDY IN 'CANCER RESEARCH' THAT INDICATES A WAY AROUND THIS. THE RESEARCH SHOWS THAT ELIMINATING OR BLOCKING AN ENZYME CALLED ALDOLASE A LOWERS ACTIVITY OF HIF-1 AND INHIBITS THE GROWTH OF BREAST CANCER TUMORS. ALDOLASE A IS AN ESPECIALLY PROMISING DRUG TARGET BECAUSE INHIBITING IT WOULD ESSENTIALLY STARVE THE TUMOR. NEW DRUG COMBINATION SHOWS PROMISE AGAINST CHILDHOOD BRAIN CANCER. MEDULLOBLASTOMA IS THE MOST COMMON MALIGNANT BRAIN CANCER IN CHILDREN, BUT SUCCESS RATES FOR TREATING THIS CANCER, DIAGNOSED IN ABOUT 400 CHILDREN PER YEAR IN THE U.S., LAG BEHIND THOSE FOR OTHER PEDIATRIC CANCERS. RESEARCH LED BY ROBERT WECHSLER-REYA, PH.D., USED HIGH-THROUGHPUT SCREENING TO LOOK FOR DRUGS THAT KILL CANCER CELLS FROM THE MOST DEADLY TYPE OF MEDULLOBLASTOMA, CALLED GROUP 3. THIS SCREEN IDENTIFIED A DRUG COMBINATION, HISTONE DEACETYLASE INHIBITORS AND PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS THAT MAY INHIBIT TUMOR GROWTH. THE FINDINGS, PUBLISHED IN 'CANCER CELL', ARE EXPECTED TO LEAD TO A CLINICAL TRIAL SOON BECAUSE BOTH DRUGS ARE ALREADY APPROVED BY THE FDA. SUPER-ONCOGENIC PROTEIN THAT PROMOTES DEVELOPMENT OF MELANOMA. MELANOMA IS THE MOST DEADLY FORM OF SKIN CANCER, CAUSING APPROXIMATELY 10,000 DEATHS PER YEAR IN THE U.S. ZEEV RONAI, PH.D., HAS STUDIED A MELANOMA-PROMOTING PROTEIN CALLED ATF2 FOR DECADES, ILLUSTRATING HOW IT DRIVES CANCER BY REGULATING GENES. HOWEVER, RESEARCH PUBLISHED IN 'CELL REPORTS' SHOWS THAT IN SOME MELANOMAS, ATF2 IS MUTATED IN A WAY THAT MAKES IT UNABLE TO AFFECT GENE ACTIVITY, BUT IT STILL PROMOTES CANCER. THE FINDINGS MAY AID IN THE DEVELOPMENT OF NOVEL THERAPIES FOR MELANOMA DRIVEN BY THIS MUTANT FORM OF ATF2. DISORDERS OF METABOLISM DIABETES DRUGS WEIGHT-LOSS EFFECTS REQUIRE DIFFERENT PARTS OF THE BRAIN THAN PREVIOUSLY THOUGHT. CERTAIN TYPE 2 DIABETES DRUGS CALLED GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RAS) PROMOTE WEIGHT LOSS, BUT HOW THEY DO THIS REMAINS POORLY UNDERSTOOD. INSIGHT INTO HOW THESE DRUGS WORK IN THE BODY - AND ESPECIALLY THE BRAIN - COULD HELP CREATE NEW DRUGS THAT EFFECTIVELY CONTROL BODY WEIGHT. GLP-1RAS CAUSE PEOPLE TO EAT LESS, AND THEIR WEIGHT LOSS EFFECTS WERE THOUGHT TO RELY ON THE HYPOTHALAMUS, A PART OF THE BRAIN THAT REGULATES APPETITE. JULIO AYALA, PH.D., PUBLISHED A STUDY IN 'DIABETES' SHOWING THAT THE HYPOTHALAMUS ISNT ESSENTIAL FOR GLP-1RAS TO REDUCE FOOD INTAKE. THE FINDINGS INDICATE THAT EFFECTIVE WEIGHT LOSS DRUGS MUST ACT ON OTHER AREAS OF THE BRAIN. GENERATING GOOD FAT BY PUSHING THE RIGHT BUTTONS. AS A WEIGHT LOSS STRATEGY, SCIENTISTS ARE TRYING TO TURN ENERGY-STORING WHITE FAT INTO ENERGY-BURNING BROWN FAT-ESSENTIALLY TURNING IT BEIGE. SHEILA COLLINS, PH.D., PUBLISHED A STUDY IN THE 'JOURNAL OF CLINICAL INVESTIGATION' REVEALING MOLECULAR DETAILS OF HOW THIS CAN HAPPEN. THE PROCESS INVOLVES A SIGNALING PROTEIN CALLED PKA THAT TURNS ON A COMPLEX CALLED MTORC1. THIS FINDING IS SURPRISING BECAUSE MTORC1 IS ALSO ACTIVATED BY GROWTH-PROMOTING SIGNALS LIKE INSULIN, WHILE FAT 'BROWNING' WAS THOUGHT TO OPPOSE GROWTH. THE RESULTS HELP DETERMINE WHICH STEPS COULD BE TARGETED BY FUTURE ANTI-OBESITY DRUGS. FAILING HEARTS SWITCH FUELS TO GENERATE ENERGY. MORE THAN 5 MILLION PEOPLE IN THE UNITED STATES SUFFER FROM HEART FAILURE, ACCORDING TO THE AMERICAN HEART ASSOCIATION, AND LESS THAN HALF SURVIVE FIVE YEARS AFTER DIAGNOSIS. MOST CURRENT TREATMENTS ARE AIMED AT THE LATER STAGES OF DISEASE, BUT RESEARCH FROM DANIEL KELLY, PH.D., PUBLISHED IN 'CIRCULATION', COULD LEAD TO A NEW APPROACH TO TREAT IT EARLIER. THE STUDY FOUND THAT AS THE HEART FAILS, IT LOSES ITS ABILITY TO BURN FATTY ACIDS AND INSTEAD STARTS USING AN ALTERNATIVE ENERGY SOURCE CALLED KETONE BODIES. ITS NOT CLEAR YET WHETHER THIS SWITCH HELPS COMPENSATE FOR DEFECTS OR MAKES THEM WORSE, BUT FURTHER EXPLORATION OF THE ISSUE COULD IDENTIFY NEW THERAPEUTIC TARGETS. FEAST OR FAMINE: THE SWITCH THAT HELPS YOUR LIVER ADAPT. IN METABOLIC CONDITIONS LIKE OBESITY AND DIABETES, THE RESPONSE TO STRESS HORMONES, ALSO CALLED GLUCOCORTICOIDS, IS ALTERED IN WAYS THAT AGGRAVATE DISEASE. THIS INCREASES THE RISK FOR LIVER DISEASE THAT CAN PROGRESS TO FIBROSIS OR LIVER CANCER. TIMOTHY OSBORNE, PH.D., PUBLISHED A STUDY IN 'CELL METABOLISM' SHOWING HOW THE LIVER RESPONDS TO GLUCOCORTICOIDS. BY LOOKING AT GENE ACTIVITY CHANGES ASSOCIATED WITH FASTING, THE RESEARCH IDENTIFIED SETDB2, A GENE THAT ENCODES AN ENZYME THAT CONTROLS WHETHER OTHER GENES CAN BE READ. THE FINDINGS SUGGEST THAT INHIBITING SETDB2 COULD PREVENT THE METABOLIC SIDE EFFECTS OF STEROID MEDICATIONS, SUCH AS WEIGHT GAIN AND INSULIN RESISTANCE. IMMUNITY PROTEIN THAT DIALS IMMUNE RESPONSES UP AND DOWN. RESEARCH LED BY LINDA BRADLEY AND PUBLISHED IN 'IMMUNITY' SHEDS NEW LIGHT ON WHY T CELLS FAIL TO CLEAR CHRONIC INFECTIONS AND ELIMINATE TUMORS. BRADLEYS LAB DISCOVERED A PROTEIN ON THE SURFACE OF T CELLS, P-SELECTIN GLYCOPROTEIN LIGAND-1 (PSGL-1), THAT ACTS AS A NEGATIVE REGULATOR OF T CELL FUNCTION. PSGL-1 IS REQUIRED TO INCREASE LEVELS OF IMMUNE CHECKPOINTS - THE PATHWAYS IN THE IMMUNE SYSTEM THAT KEEP T CELL RESPONSES UNDER CONTROL. THE RESEARCH SUGGESTS THAT PSGL-1 INHIBITORS MAY ENHANCE THE IMMUNE RESPONSE TO CANCER AND CHRONIC VIRAL INFECTIONS SUCH AS HEPATITIS. IT ALSO SUGGESTS THAT BOOSTING PSGL-1 MAY BE A STRATEGY TO TREAT AUTOIMMUNE DISEASES. WHY HIV IS NOT CLEARED BY THE IMMUNE SYSTEM. FOR DECADES, HIV RESEARCHERS HAVE KNOWN THAT THE INITIAL IMMUNE RESPONSE TO HIV FAILS TO PREVENT THE VIRUS FROM REPLICATING, BUT THE REASONS WHY WERE UNCLEAR. SUMIT CHANDA, PH.D., PUBLISHED A PAPER IN 'CELL HOST & MICROBE' SHOWING THAT A PROTEIN IN IMMUNE CELLS CALLED NLRX1 ACTUALLY REPRESSES THE INITIAL IMMUNE RESPONSE TRIGGERED BY VIRAL DNA. THE DISCOVERY COULD LEAD TO BETTER ANTIVIRAL DRUGS OR WAYS TO IMPROVE VACCINES AGAINST HIV OR OTHER VIRUSES. IT COULD ALSO INFORM THE DEVELOPMENT OF FUTURE CANCER THERAPIES BECAUSE NLRX1 IS PART OF A SIGNALING PATHWAY THAT CAN ENHANCE IMMUNE RESPONSES AGAINST CANCER CELLS. NEUROSCIENCE AND AGING POTENTIAL WAY TO SLOW ADVANCE OF ALZHEIMERS. HUAXI XU, PH.D., HAS PUBLISHED RESEARCH IN 'THE JOURNAL OF NEUROSCIENCE' THAT SUGGESTS A NEW WAY TO MINIMIZE THE GENERATION OF AMYLOID-BETA AND SLOW THE ADVANCE OF ALZHEIMERS DISEASE. DEPOSITS OF AMYLOID-BETA IN THE BRAIN ARE A PATHOGENIC HALLMARK OF ALZHEIMERS DISEASE. THE STUDY FOUND THAT A RECEPTOR CALLED SORLA, WITH ITS PARTNER SNX27, MOVES THE AMYLOID PRECURSOR PROTEIN AWAY FROM THE ACIDIC COMPARTMENT, WHERE IT IS PROCESSED INTO AMYLOID BETA, TO A DIFFERENT LOCATION WHERE IT CANNOT BE CUT. MODULATING THE TRAFFICKING OF THE AMYLOID PRECURSOR PROTEIN THROUGH SORLA MAY BE A NEW THERAPEUTIC APPROACH FOR ALZHEIMERS DISEASE. DIETARY RESTRICTION INCREASES LIFESPAN THROUGH EFFECTS ON THE GUT. DIETARY RESTRICTION LENGTHENS HEALTHY LIFESPAN IN MANY SPECIES, INCLUDING HUMANS. EATING LESS INCREASES THE RATE AT WHICH CELLS RECYCLE THEIR COMPONENTS BY A PROCESS CALLED AUTOPHAGY. TO DETERMINE IN WHICH ORGANS AUTOPHAGY MATTERS MOST, MALENE HANSEN, PH.D., BLOCKED AUTOPHAGY IN THE INTESTINES OF TINY WORMS CALLED C. ELEGANS, AND FOUND THAT DIETARY RESTRICTION NO LONGER EXTENDED LIFESPAN. THE RESULTS, PUBLISHED IN 'PLOS GENETICS', SHOW THAT AUTOPHAGY IN THE GUT IS ESSENTIAL TO PRESERVE ITS BARRIER FUNCTION, WHICH PREVENTS HARMFUL MICROBES AND TOXINS FROM REACHING THE REST OF THE BODY. THE FINDINGS COULD EVENTUALLY LEAD TO NEW TREATMENTS THAT HELP PEOPLE LIVE LONGER, HEALTHIER LIVES. SCIENTIFIC BREAKTHROUGH MAY LIMIT DAMAGE CAUSED BY HEART ATTACKS. HEART ATTACKS DESTROY H |
| FORM 990, PART VI, LINE 11B | PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CHIEF FINANCIAL OFFICER AND THE AUDIT COMMITTEE OF THE BOARD OF TRUSTEES AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. |
| FORM 990, PART VI, LINE 12C | DESCR OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST CONFLICT OF INTEREST STATEMENTS ARE GIVEN TO MANAGEMENT STAFF AND PRINCIPAL INVESTIGATORS ON A PERIODIC BASIS TO REPORT ON CONFLICTS OR LACK OF CONFLICTS. THE STATEMENTS ARE REVIEWED ANNUALLY BY THE SENIOR DIRECTOR, INTELLECTUAL PROPERTY AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, WITH A SUMMARY OF THE REVIEW PROVIDED TO THE CFO. AN ASSESSMENT IS MADE AS TO WHETHER A CONFLICT CAN BE MANAGED BY THE EXISTING DEPARTMENTS AND PRACTICES. CONFLICTS ARE BROUGHT TO THE BOARD OF TRUSTEES ON AN AS NEEDED BASIS. CONFLICTS AND POTENTIAL CONFLICTS THAT INVOLVE THE CEO OR THE PRESIDENT ARE BROUGHT TO THE BOARD OF TRUSTEES TO ADDRESS ANY ACTUAL OR POTENTIAL POSSIBILITY THAT THE DESIGNATED REVIEWERS (I.E., SENIOR DIRECTOR, INTELLECTUAL PROPERTY AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, AND THE CFO) COULD BE PRESSURED TO MAKE BIASED DECISIONS IN MANAGING CONFLICTS INVOLVING THE CEO OR PRESIDENT. AS TO RESTRICTIONS IMPOSED: THE INSTITUTE WILL EMPLOY THE MECHANISM THAT IS THE BEST FIT WITH THE FACTS AND CIRCUMSTANCES OF ANY IDENTIFIED CONFLICT OF INTEREST. METHODS TO MANAGE POTENTIAL CONFLICTS/ENFORCEMENT MECHANISM: REVIEWING MANAGEMENT IS RESPONSIBLE FOR MANAGING, REDUCING, OR ELIMINATING REAL OR POTENTIAL CONFLICTS OF INTEREST. EXAMPLES OF CONDITIONS OR RESTRICTIONS THAT MIGHT BE IMPOSED TO MANAGE, REDUCE, OR ELIMINATE CONFLICTS OF INTERESTS INCLUDE: -PUBLIC DISCLOSURE OF SIGNIFICANT FINANCIAL INTERESTS -MONITORING OF RESEARCH BY INDEPENDENT REVIEWERS -MODIFICATION OF THE RESEARCH PLAN -DISQUALIFICATION FROM PARTICIPATION IN THE PORTION OF FUNDED RESEARCH THAT COULD BE AFFECTED BY SIGNIFICANT FINANCIAL INTEREST -DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS -SEVERANCE OF RELATIONSHIPS THAT CREATE ACTUAL OR POTENTIAL CONFLICTS -REVIEW OF COMMERCIAL SPONSORED RESEARCH AGREEMENTS FOR SCIENTIFIC MERIT BY THE PROGRAM PLANNING COMMITTEE -REMOVAL OF AN AFFECTED PARTY FROM NEGOTIATION WITH A COMPANY WITH WHICH HE/SHE HAS SIGNIFICANT FINANCIAL INTEREST. |
| FORM 990, PART VI, LINE 15A & 15B | PROCESS FOR DETERMINING COMPENSATION COMPENSATION FOR THE CEO, THE PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF FOUR INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEOS COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON MAY 25, 2016 FOR THE FOLLOWING POSITIONS: 1) CEO 2) PRESIDENT 3) CFO 4) SVP HUMAN RESOURCES 5) VP STRATEGIC ALLIANCE 6) SVP DRUG DISCOVERY & DEVELOPMENT 7) SCIENTIFC DIRECTOR/PROFESSOR 8) CENTER DIRECTOR, LA JOLLA PROFESSOR 9) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR |
| FORM 990, PART VI, LINE 19 | PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST. |
| Software ID: | |
| Software Version: |